Literature DB >> 11422740

Effects of 1,25(OH)2D3 in experimental mesangial proliferative nephritis in rats.

V Panichi1, M Migliori, D Taccola, C Filippi, L De Nisco, L Giovannini, R Palla, C Tetta, G Camussi.   

Abstract

BACKGROUND: 1,25-Dihydroxyvitamin D3 [1,25(OH)2D3], the active form of vitamin D3, is a potent immunomodulatory agent on several cell types such as monocytes and mesangial cells. Recruitment of inflammatory cells, as well as stimulation of resident cells and mesangial matrix accumulation are key features of various experimental and human glomerular diseases. Here we show that 1,25(OH)2D3 attenuates the morphologic and functional alterations in anti-Thy-1.1. nephritis, an experimental model of mesangial proliferative glomerulonephritis.
METHODS: The anti-Thy-1.1 group (group I) comprised 24 rats that at day 0 received 0.5 mL of saline containing 400 microg of monoclonal antibodies (mAb) anti-Thy-1.1 IgG. The anti-Thy-1.1 treated with 1,25(OH)2D3 group (group II) were 24 rats given 1,25(OH)2D3 at the dose of 25 ng/100 g body wt/day, from day -3 to day 14. At day 0, the rats received 400 microg of anti-Thy-1.1 monoclonal IgG. The control group (group III) comprised 12 rats injected with vehicle alone; the control group treated with 1,25(OH)2D3 (group IV)-12 rats were given 1,25(OH)2D3 as in group II without mAb administration. Proteinuria and urinary interleukin-6 excretion were measured daily. Blood urea nitrogen and creatinine, creatinine clearance, calcium, and phosphate were measured at days 0, 4, 7, and 14. In addition to conventional periodic acid-Schiff staining, binding of anti-Thy-1.1 IgG and C3b complement fraction, His48- and ED1-positive cells were studied by immunofluorescence. Mesangial proliferation was studied by the proliferating cell nuclear antigen (PCNA) technique. Apoptosis was evaluated by the TUNEL assay.
RESULTS: The anti-Thy-1.1 treated with 1,25(OH)2D3 group versus the anti-Thy-1.1 alone group showed a significant reduction in urinary protein (at day 7, 424 +/- 228 vs. 66 +/- 30 mg/mg urinary creatinine, P = 0.02) and interleukin-6 excretion (at day 3, 537 +/- 360 pg/mL vs. 110 +/- 34 pg/mg urinary creatinine, P = 0.015), reduced glomerular diameters (at day 7, 283 +/- 38 vs. 261 +/- 48 microm, P < 0.01), decreased neutrophil (at day 4, 20 +/- 12 His48-positive cells/glomerulus vs. 3.7 +/- 1.3 His48-positive cells/glomerulus, P < 0.001), and monocyte accumulation (day 7, 4.9 +/- 2.9 ED1-positive cells/glomerulus vs. 2.8 +/- 2.9 ED1-positive cells/glomerulus, P < 0.05), and attenuated glomerular cells proliferation (day 7, 13 +/- 3.2 PCNA-positive cells/glomerulus vs. 9.4 +/- 3 PCNA-positive cells/glomerulus, P < 0.01). Apoptosis showed a biphasic behavior with an early peak at day 4 in the anti-Thy-1.1 group (2.3 +/- 2.2 TUNEL-positive cells/glom) related to cellular lysis and a late peak at day 14 related to the recovery phase.
CONCLUSIONS: 1,25(OH)2D3 can reduce glomerular hypercellularity, inflammatory infiltration in anti-Thy-1.1 nephritis, preserving the apoptotic response of the reparative phase.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11422740     DOI: 10.1046/j.1523-1755.2001.00775.x

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  34 in total

Review 1.  Nuclear receptors in renal disease.

Authors:  Moshe Levi
Journal:  Biochim Biophys Acta       Date:  2011-04-14

2.  Therapeutic role and potential mechanisms of active Vitamin D in renal interstitial fibrosis.

Authors:  Xiaoyue Tan; Yingjian Li; Youhua Liu
Journal:  J Steroid Biochem Mol Biol       Date:  2007-01-05       Impact factor: 4.292

3.  25-hydroxyvitamin D levels, race, and the progression of kidney disease.

Authors:  Michal L Melamed; Brad Astor; Erin D Michos; Thomas H Hostetter; Neil R Powe; Paul Muntner
Journal:  J Am Soc Nephrol       Date:  2009-10-29       Impact factor: 10.121

4.  Serum fibroblast growth factor-23 is associated with incident kidney disease.

Authors:  Casey M Rebholz; Morgan E Grams; Josef Coresh; Elizabeth Selvin; Lesley A Inker; Andrew S Levey; Paul L Kimmel; Ramachandran S Vasan; John H Eckfeldt; Harold I Feldman; Chi-Yuan Hsu; Pamela L Lutsey
Journal:  J Am Soc Nephrol       Date:  2014-07-24       Impact factor: 10.121

5.  TRAF3 Modulation: Novel Mechanism for the Anti-inflammatory Effects of the Vitamin D Receptor Agonist Paricalcitol in Renal Disease.

Authors:  Sandra Rayego-Mateos; Jose Luis Morgado-Pascual; José Manuel Valdivielso; Ana Belén Sanz; Enrique Bosch-Panadero; Raúl R Rodrigues-Díez; Jesús Egido; Alberto Ortiz; Emilio González-Parra; Marta Ruiz-Ortega
Journal:  J Am Soc Nephrol       Date:  2020-07-06       Impact factor: 10.121

6.  Vitamin D receptor agonist doxercalciferol modulates dietary fat-induced renal disease and renal lipid metabolism.

Authors:  Xiaoxin X Wang; Tao Jiang; Yan Shen; Hannah Santamaria; Nathaniel Solis; Cynthia Arbeeny; Moshe Levi
Journal:  Am J Physiol Renal Physiol       Date:  2011-01-05

7.  Neutrophil responses to injury or inflammation impair peripheral gustatory function.

Authors:  P W Steen; L Shi; L He; L P McCluskey
Journal:  Neuroscience       Date:  2010-02-26       Impact factor: 3.590

8.  Vitamin D status and outcomes after renal transplantation.

Authors:  Frank Bienaimé; Delphine Girard; Dany Anglicheau; Guillaume Canaud; Jean Claude Souberbielle; Henri Kreis; Laure Hélène Noël; Gérard Friedlander; Caroline Elie; Christophe Legendre; Dominique Prié
Journal:  J Am Soc Nephrol       Date:  2013-03-28       Impact factor: 10.121

9.  1, 25-dihydroxyvitamin D3 decreases adriamycin-induced podocyte apoptosis and loss.

Authors:  Min-shu Zou; Jian Yu; Guo-ming Nie; Wei-sun He; Li-man Luo; Hong-tao Xu
Journal:  Int J Med Sci       Date:  2010-08-24       Impact factor: 3.738

Review 10.  Emerging risk factors and markers of chronic kidney disease progression.

Authors:  Florian Kronenberg
Journal:  Nat Rev Nephrol       Date:  2009-12       Impact factor: 28.314

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.